Symptomatic intraocular pressure dysregulation during clopidogrel exposure after patent foramen ovale closure in a patient with ocular hypertension and angle crowding: a Case Report - Report - MDSpire

Intraocular Pressure Dysregulation Symptoms Associated with Clopidogrel Treatment Following Patent Foramen Ovale Closure in a Patient with Ocular Hypertension and Angle Crowding: A Case Study

  • By

  • Faxue Li

  • Rongbo Yu

  • Xuan Guo

  • Wenyi Ji

  • Qiang Wu

  • July 16, 2026

Share

Clinical Report: Intraocular Pressure Dysregulation Symptoms Associated with Clopidogrel

Overview

This case study describes a 52-year-old woman who experienced recurrent ocular discomfort and elevated intraocular pressure (IOP) after clopidogrel treatment following patent foramen ovale closure. Symptoms improved upon clopidogrel withdrawal and recurred after re-administration.

Background

Clopidogrel is commonly prescribed for antiplatelet therapy post-structural heart interventions, yet non-hemorrhagic ocular adverse events are rarely reported.

Data Highlights

No numerical data or trial data available in the article.

Key Findings

  • A 52-year-old woman developed ocular discomfort and blurred vision after clopidogrel treatment.
  • Baseline assessment indicated ocular hypertension with angle crowding but no glaucomatous damage.
  • 24-hour IOP monitoring showed marked peak elevation and diurnal fluctuation during symptomatic exposure.
  • Symptoms improved after clopidogrel withdrawal and recurred upon re-administration.
  • This case represents a temporal association rather than definitive evidence of clopidogrel-induced IOP dysregulation.

Clinical Implications

Clinicians should be aware of the potential for clopidogrel to induce IOP dysregulation in patients with pre-existing ocular hypertension. Monitoring IOP in such patients during clopidogrel therapy may be warranted.

Conclusion

This case presents observations regarding the ocular effects of clopidogrel in a patient with risk factors for elevated IOP.

Related Resources & Content

  1. Frontiers in Ophthalmology, 2026 -- Symptomatic intraocular pressure dysregulation during clopidogrel exposure after patent foramen ovale closure in a patient with ocular hypertension and angle crowding: a Case Report
  2. Glaucoma Physician — A Case of a Young Man With Angle Closure Glaucoma, Plateau Iris, and Pilocarpine Intolerance
  3. Frontiers in Ophthalmology — Advanced bilateral glaucoma decades after first-generation Fyodorov ‘collar-button’ anterior–posterior phakic intraocular lens implantation: a case report and clinical management considerations
  4. New Retinal Physician — Minimizing the Risk of Angle Closure Due to Dilation
  5. the ophthalmologist — Fellow Eyes Reveal Angle Closure Clues
  6. European Stroke Organisation (ESO) Guidelines on the diagnosis and management of patent foramen ovale (PFO) after stroke
  7. Patent foramen ovale closure vs medical therapy in secondary prevention of stroke and TIA: A systematic review and meta-analysis
  8. Primary Angle-Closure Disease Preferred Practice Pattern®
  9. 800.43 Shortened Duration of Dual Anti-Platelet Therapy After Percutaneous Patent Foramen Ovale and Atrial Septal Defect Closure | JACC: Cardiovascular Interventions
  10. Frontiers | Symptomatic intraocular pressure dysregulation during clopidogrel exposure after patent foramen ovale closure in a patient with ocular hypertension and angle crowding: a Case Report

Original Source(s)

Symptomatic intraocular pressure dysregulation during clopidogrel exposure after patent foramen ovale closure in a patient with ocular hypertension and angle crowding: a Case Report

  • by Faxue Li, Rongbo Yu, Xuan Guo, Wenyi Ji, Qiang Wu

  • July 16, 2026

Related Content

Marked and reversible circulating insulin-like growth factor-1 elevation during teprotumumab N01 treatment for thyroid eye disease with limited correspondence to glycemic changes

ORG Detects Retinal Dysfunction Before Structural Changes

At ASRS 2026, Kareem Moussa, MD, presented early data suggesting optoretinography may identify photoreceptor dysfunction in diabetic eyes before conventional imaging reveals abnormalities.

Merck Highlights Early Tiespectus Data

At the ASRS meeting in Montreal, Baruch D. Kuppermann, MD, PhD, presented BRVO findings from the phase 1/2a RIOJA program evaluating the investigational VEGF/Tie2 bispecific.